How Farmer Mac’s New US$290 Million Guaranteed Securitization Structure At Federal Agricultural Mortgage (AGM) Has Changed Its Investment Story

• Earlier this week, Federal Agricultural Mortgage (Farmer Mac) completed a US$313.5 million agricultural mortgage-backed securitization, pooling 343 loans and issuing a US$290.0 million senior tranche guaranteed by the company.
• By tailoring the guaranteed senior tranche into three classes and hinting at a new 2026 product, Farmer Mac is signaling efforts to broaden investor appeal while supporting liquidity for rural borrowers.
• Next, we’ll examine how this guaranteed US$290.0 million securitization shapes Federal Agricultural Mortgage’s investment narrative and future growth drivers.

Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Federal Agricultural Mortgage Investment Narrative Recap

To own Federal Agricultural Mortgage, you need to believe in long term demand for agricultural and rural credit, supported by its government sponsored enterprise status and perceived funding advantage. The new US$313.5 million securitization looks additive rather than transformational in the near term, incrementally supporting loan growth but not changing the key short term swing factors of credit quality and regulatory risk.

The most relevant recent announcement alongside this deal is Farmer Mac’s Q3 2025 earnings, which showed year to date net income of US$159.49 million and continued profitability. That earnings resilience provides some cushion as the company leans further into securitizations and newer segments like broadband and infrastructure finance, where any uptick in credit losses or CECL allowances could affect margins and temper the benefits of new product offerings.

Yet behind Farmer Mac’s steady earnings and new securitizations, investors should be aware of rising portfolio risk in newer segments like broadband and infrastructure…

Read the full narrative on Federal Agricultural Mortgage (it's free!)

Federal Agricultural Mortgage's narrative projects $514.9 million revenue and $239.2 million earnings by 2028. This requires 11.8% yearly revenue growth and a $52.9 million earnings increase from $186.3 million today.

Uncover how Federal Agricultural Mortgage's forecasts yield a $226.00 fair value, a 28% upside to its current price.

Exploring Other Perspectives

Five fair value estimates from the Simply Wall St Community span from about US$135.90 to over US$126,000 per share, showing just how far apart individual views can be. Against that wide spread, the recent securitization and ongoing expansion into new rural finance segments highlight how differently people may weigh growth opportunities versus the risk of higher credit losses and changing regulation when assessing Farmer Mac’s future performance.

Explore 5 other fair value estimates on Federal Agricultural Mortgage - why the stock might be a potential multi-bagger!

Build Your Own Federal Agricultural Mortgage Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Federal Agricultural Mortgage research is our analysis highlighting 6 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Federal Agricultural Mortgage research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Federal Agricultural Mortgage's overall financial health at a glance.

Seeking Other Investments?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Find companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com